TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 4.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

On a per-share basis, the Morrisville, New York-based company said it had profit of 2 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts.